Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have received a consensus rating of “Moderate Buy” from the fifteen brokerages that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $56.36.

KYMR has been the subject of several recent research reports. HC Wainwright lifted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Stephens reiterated an “overweight” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Citigroup began coverage on Kymera Therapeutics in a report on Thursday, March 13th. They set a “buy” rating and a $52.00 price target on the stock. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Friday, December 27th.

Kymera Therapeutics Stock Performance

KYMR stock opened at $24.12 on Tuesday. The firm has a fifty day moving average price of $31.62 and a 200 day moving average price of $39.76. Kymera Therapeutics has a fifty-two week low of $19.45 and a fifty-two week high of $53.27. The firm has a market cap of $1.57 billion, a PE ratio of -10.31 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. On average, equities analysts predict that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Activity

In other news, COO Jeremy G. Chadwick sold 1,383 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Ellen Chiniara sold 2,241 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the sale, the insider now directly owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. This trade represents a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,659 shares of company stock valued at $324,567. Corporate insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors have recently added to or reduced their stakes in KYMR. Blue Trust Inc. lifted its holdings in shares of Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after purchasing an additional 270 shares during the last quarter. State of Wyoming purchased a new stake in Kymera Therapeutics in the fourth quarter valued at about $45,000. GF Fund Management CO. LTD. acquired a new stake in Kymera Therapeutics in the fourth quarter worth about $55,000. KBC Group NV grew its stake in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after acquiring an additional 752 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Kymera Therapeutics by 95.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company’s stock valued at $194,000 after acquiring an additional 2,350 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.